This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: April 6, 2009
Last updated: September 27, 2010
Last verified: September 2010
PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.

Condition Intervention Phase
Asthma Drug: PF-03526299 Drug: Placebo Drug: Fluticasone propionate Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, 3-Way Crossover Study To Determine The Effects Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects.

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Spirometry pre- and post- bronchial allergen challenge [ Time Frame: 2 months ]

Secondary Outcome Measures:
  • Laboratory safety tests [ Time Frame: 2 months ]
  • 12-lead ECGs [ Time Frame: 2 months ]
  • Adverse Event reporting [ Time Frame: 2 months ]
  • Blood samples for pharmacokinetic measurement [ Time Frame: 2 months ]
  • Sputum for pharmacodynamic measurement [ Time Frame: 2 months ]

Enrollment: 29
Study Start Date: June 2009
Study Completion Date: July 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PF-03526299 Drug: PF-03526299
Inhaled, two doses 4 hours apart
Placebo Comparator: Placebo Drug: Placebo
Inhaled, two doses 4 hours apart
Active Comparator: Fluticasone propionate Drug: Fluticasone propionate


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females 18-60 years
  • Mild asthma
  • Atopic to allergens

Exclusion Criteria:

  • Unstable asthma
  • Smokers or recent ex-smokers
  • Recent allergen challenge
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00877539

United Kingdom
Pfizer Investigational Site
London, United Kingdom, SE1 1YR
Pfizer Investigational Site
Manchester, United Kingdom, M23 9QZ
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00877539     History of Changes
Other Study ID Numbers: A9291002
Study First Received: April 6, 2009
Last Updated: September 27, 2010

Keywords provided by Pfizer:
Asthma Allergen Challenge

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents processed this record on July 21, 2017